HK$11.28 after hours: 2228.HK XtalPi (HKSE) 09 Feb 2026 AI stocks

2228.HK stock opened eyes after-hours at HK$11.28 on 09 Feb 2026, sitting near a 50-day average of HK$10.89 with 47,105,134 shares traded today. The Hong Kong-listed AI drug discovery firm XtalPi Holdings Ltd (HKSE) shows strong short-term momentum but mixed fundamentals. We examine valuation, technical signals and model forecasts to show where the stock fits an AI-stocks strategy for Hong Kong investors.

Quick take: 2228.HK stock price action and market context

XtalPi Holdings (2228.HK) closed HK$11.28 with a trading range today between HK$11.13 and HK$11.57. Market cap stands at HK$48,542,033,464 and average daily volume is 74,321,788 shares, indicating current liquidity. The stock is up 12.91% year-to-date and has gained 52.02% over six months, putting it among higher momentum names in Hong Kong’s healthcare AI niche.

Business model and AI drug-discovery edge

XtalPi provides AI-driven drug discovery and laboratory automation platforms including XMolGen, XtalFold and Xtalgazer. The company serves clients across China, the United States, Europe, South Korea and Japan and targets small molecules, antibodies, peptides, ADC and PROTAC modalities. This AI focus positions 2228.HK stock in the healthcare-technology crossover, where long development timelines meet high-margin software and services opportunities.

Financials and valuation for 2228.HK stock

Revenue rose to CNY266.43 million in 2024, up 52.75% year-on-year while reported losses narrowed to CNY1.52 billion. On the HKSE the share metrics show EPS HK$1.05 and a trailing PE of 10.74, but price-to-sales sits at 63.28 and price-to-book at 5.39, reflecting high growth premium. Liquidity metrics are strong: current ratio 9.69 and cash per share HK$0.92. These mixed signals mean valuation must be read with the company’s roadmap to commercial drug discovery revenue in mind.

Technical snapshot and trading signals for 2228.HK stock

Short-term momentum is strong: RSI 76.82 (overbought), MACD histogram 0.35 and ADX 30.64 indicating a firm trend. The 50-day and 200-day averages are HK$10.89 and HK$8.87 respectively, with Bollinger upper band at HK$11.80. Year high is HK$15.12, year low HK$3.85. Traders should note high MFI 79.67 and a relative volume of 0.51 before adding exposure.

Meyka AI rates 2228.HK with a score out of 100 and forecasts

Meyka AI rates 2228.HK with a score of 63.15 out of 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects monthly HK$14.10, quarterly HK$13.43 and yearly HK$10.47. Versus the current price HK$11.28, that implies a +25.00% monthly upside, +19.06% quarterly upside and -7.18% year downside. Forecasts are model-based projections and not guarantees.

Risks and catalysts for AI-stocks investors

Key catalysts include new partnerships, commercialization wins and progress on platform validation with drug partners; an earnings update is scheduled for 27 Mar 2026. Main risks are a high price-to-sales multiple, long sales cycles to pharmaceutical customers and negative free cash flow per share HK$-0.13 (TTM). Balance sheet strength and low debt (debt-to-equity 0.05) reduce near-term solvency risk, but execution and revenue mix will determine valuation re-rating.

Final Thoughts

XtalPi (2228.HK) is an AI-first drug discovery play listed on the HKSE that combines software and lab automation. At HK$11.28, the shares show strong short-term momentum but carry valuation tension: trailing PE 10.74 coexists with a sky-high price-to-sales 63.28. Technicals point to near-term strength while fundamentals require continued revenue conversion. Meyka AI’s model projects monthly HK$14.10 (+25.00% vs current price) but a yearly HK$10.47 (-7.18% vs current price), highlighting scenario risk. For AI-stocks strategies, 2228.HK stock fits a thematic growth sleeve for investors willing to accept volatility and execution risk. Use position sizing, monitor the 50-day moving average HK$10.89, and track the 27 Mar 2026 earnings announcement. Meyka AI, our AI-powered market analysis platform, supports these scenario views but forecasts are not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.